ClinicalTrials.gg
CompletedNCT05549232Updated Jul 23, 2025Results posted

Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital

An observational study in Hematologic Neoplasms and Burns, sponsored by Hemanext. Completed at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by Hemanext · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
22
Ages
18 Years and older
Sex
All
01

Study summary

The overall objective of this study is to collect preliminary safety data on the transfusion of hypoxic RBCs, manufactured with the Hemanext ONE device, in patients with burns and patients with hematological malignancies. The Hemanext ONE device received CE mark in April 2021.

Read the detailed description

The primary objective is to assess hypoxic RBCs safety and tolerance assessment up to 24 hours following the transfusion initiation and overall up to 7 days (+/- 1 day) after the transfusion episode (single transfusion course).

Secondary objectives include the following.

  1. Assessment of pre and post transfusion hemoglobin levels
  2. Assessment of hemoglobin level before the following transfusion, if applicable
  3. Assessment of AEs occurrence:

    i. Up to 7 days (+/- 1 day) post transfusion, in comparison with historical control (including but not limited to infection, deep vein thrombosis, acute respiratory distress syndrome, transfusion-related acute lung injury, transfusion associated circulatory overload, anaphylactic shock, acute hemolytic transfusion reaction).

    ii. Up to the subsequent transfusion episode or up to 28 days (+/- 1 day) after the initial transfusion, whichever comes first.

    iii. From enrollment, up to their subsequent transfusion or 28 days (+/- 1 day) post transfusion, whichever comes first, through the assessment of patient's diary.

  4. Assessment of the vital signs during and up to 15 minutes after the transfusion.
02

Conditions studied

  • Hematologic Neoplasms
  • Burns

Keywords

  • Transfusion
  • Red Blood Cells
  • Hypoxic
03

In context

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

This study's enrollment of 22 is below the median of 191 across 324 observational studies indexed under Hematologic Neoplasms.

Browse Hematologic Neoplasms studies →

Lead sponsor

Hemanext is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

10 acute burn patients and 10 patients with hematological malignancies, who require transfusion of red cells concentrates and who fulfill all eligibility criteria will be enrolled in this clinical investigation at Haukeland University Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A. Hematological patients group:

  1. Male or female patients at least 18 years of age
  2. Patients expected to require > 2 units of red blood cells in a single transfusion event
  3. Patients who have the capacity to consent to participate and are willing to comply with the study procedures.
  4. Patients identified by a Transfusion trigger of less than 9 g/dL
  5. Patients with a documented diagnosis of leukemia, myelomatosis or MDS requiring chronic transfusions

B. Burn patients group:

  1. Male or female patients at least 18 years of age
  2. Patients who have the capacity to consent by themselves to participate to the clinical investigation
  3. Smaller burn patients, hospitalized with a Total Body Surface Area (TBSA%) burn ≥ 10% and ≤ 50%
  4. Patients expected to require > 2 unit of red blood cells in a single transfusion event

Exclusion criteria

Exclusion Criteria:

A. Both patients groups

  1. Patients with any positive antibody screening test
  2. Patients for whom consent has not been obtained
  3. Patients with a known hemolytic anemia (congenital or acquired)
  4. Patients \< 18 years old
  5. Patients with a known or suspected pregnancy
  6. Patients with a history of major transfusion reactions
  7. Patients whom the Investigator deems clinical trial participation is not in their best interest.

B. Burn patients specific exclusion criteria :

  1. Patients who do not have the capacity to consent by themselves to participate to the clinical investigation
  2. Patients hospitalized with a Total body surface area (TBSA%) burn more than 50%
  3. Patients with combined trauma in need of blood transfusions for treatment other than the burn excision
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
22 participants (actual)
Patient registry
No

Groups and cohorts

  • Hematologic Malignancies

    Subjects requiring chronic transfusions with red blood cells for treatment of a hematologic malignancy will receive 1 transfusion with 2 units of hypoxic red blood cells manufactured with the Hemanext ONE device. The subjects will be monitored for all adverse events from Informed Consent through Day 28 or the subsequent standard of care transfusion, whichever occurs first.

    Device: Hypoxic Red Blood Cells

  • Acute Burn

    Subjects requiring transfusion with red blood cells during the excision procedure after an acute burn will receive 2 units of hypoxic red blood cells manufactured with the Hemanext ONE device. As the excision treatments require transfusion of more than 2 units of red blood cells, the first 2 units transfused during the procedure will be hypoxic red blood cells. The subjects will be monitored for all adverse events through Day 28.

    Device: Hypoxic Red Blood Cells

Interventions

  • DeviceHypoxic Red Blood Cells

    Hypoxic Red Blood Cells manufactured with the Hemanext ONE device- CPD/PAGGSM Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced an Adverse Event (All Types/Grades) Within a Time Frame up to 24 Hours Following the Transfusion.

    The type and the grade of each adverse event will be categorized according to: * Association for the Advancement of Blood and Biotherapies (AABB) technical manual, 20th edition (2020) * Biomedical Excellence for Safer Transfusion (BEST) Collaborative review - Lancet 2016; 388: 2825-36 * Local AEs database (for reference) * ISO 14155-2020 definitions

    Time frame: 24 hours

  2. Number of Participants Who Experienced an Adverse Event (AE) (All Types/Grades) Overall up to 7 Days (+/-1 Day) After the Transfusion.

    The type and the grade of each adverse event will be categorized according to: * Association for the Advancement of Blood and Biotherapies (AABB) technical manual, 20th edition (2020) * Biomedical Excellence for Safer Transfusion (BEST) Collaborative review - Lancet 2016; 388: 2825-36 * Local AEs database (for reference) * ISO 14155-2020 definitions

    Time frame: 7 days (+/-1 day)

Secondary outcomes

  1. Evolution of the Hemoglobin Level Before and After the Transfusion.

    The difference in measured hemoglobin (grams/dL) between pre-transfusion and up to 30 minutes post-transfusion.

    Time frame: pre-transfusion to up to 30 minutes post-transfusion

  2. Calculation of the Hemoglobin Increment After Transfusion Corrected for Patient Blood Volume and Hemoglobin Dose

    The hemoglobin increment from each transfusion will be determined by calculating the difference between the subject's post-transfusion and pre-transfusion hemoglobin (g/dL). It will then be corrected for estimated subject blood volume and the amount of Hb transfused. The following equation used for the hemoglobin increment calculation: HgB Increment = (Subject's HgB level post-transfusion - Subject's HgB pre-transfusion)/ (total HgB transfused x Subject's BloodVolume) Equations for calculating the hemoglobin increment may be found in the following publication: Wendelbo Ø, Opheim EN, Hervig T, Felli Lunde TH, Bruserud Ø, Mollnes TE, Reikvam H. Cytokine profiling and post-transfusion haemoglobin increment in patients with haematological diseases. Vox Sang. 2018 Oct;113(7):657-668. doi: 10.1111/vox.12703. Epub 2018 Aug 29. PMID: 30159896.

    Time frame: 28 days

  3. Comparison of the Hemoglobin Level Before the Index Transfusion to That Prior to the Subsequent Transfusion

    The difference in measured hemoglobin (grams/dL) between the pre-transfusion hemoglobin level for the study transfusion and the pre-transfusion hemoglobin level for the next scheduled transfusion.

    Time frame: 28 days

  4. Evaluation of AEs From Enrollment, up to Prior to the Subsequent Transfusion or up to Day 28, Whichever Occurs First

    Number of AEs that occur from enrollment, up to prior to the subsequent transfusion or up to Day 28, whichever occurs first

    Time frame: 28 days

  5. Evaluation of Subject's Blood Pressure Over the Course of the Transfusion and up to 15 Minutes Post-transfusion

    Change in blood pressure (systolic; mmHg) from baseline up to 15 minutes post-transfusion.

    Time frame: baseline up to 15 minutes post-transfusion.

  6. Evaluation of Subject's Blood Pressure Over the Course of the Transfusion and up to 15 Minutes Post-transfusion

    Change in blood pressure (diastolic; mmHg) from baseline up to 15 minutes post-transfusion.

    Time frame: baseline up to 15 minutes post-transfusion.

  7. Evaluation of Subject's Respiratory Rate Over the Course of the Transfusion and up to 15 Minutes Post-transfusion

    Change in respiratory rate (breaths per minute) from baseline to up to 15 minutes post-transfusion.

    Time frame: baseline to up to 15 minutes post-transfusion

  8. Evaluation of Subject's SO2 Level Over the Course of the Transfusion and up to 15 Minutes Post-transfusion

    Change in the amount of oxygen in the body (% S02 level), measured with a pulse oximeter, from baseline to up to 15 minutes post-transfusion.

    Time frame: baseline to up to 15 minutes post-transfusion

  9. Evaluation of Subject's Pulse Over the Course of the Transfusion and up to 15 Minutes Post-transfusion

    Change in heart rate (beats per minute) from baseline to up to 15 minutes post-transfusion

    Time frame: baseline to up to 15 minutes post-transfusion

07

Results

Posted May 18, 2025

Participant flow

Participant flow — Overall Study
MilestoneHematologic MalignanciesAcute Burn
Started1012
Completed910
Not completed12

Outcome measures

PrimaryNumber of Participants Who Experienced an Adverse Event (All Types/Grades) Within a Time Frame up to 24 Hours Following the Transfusion.

The type and the grade of each adverse event will be categorized according to: * Association for the Advancement of Blood and Biotherapies (AABB) technical manual, 20th edition (2020) * Biomedical Excellence for Safer Transfusion (BEST) Collaborative review - Lancet 2016; 388: 2825-36 * Local AEs database (for reference) * ISO 14155-2020 definitions

Time frame:
24 hours
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (All Types/Grades) Within a Time Frame up to 24 Hours Following the Transfusion.
ParticipantsHematologic MalignanciesAcute Burn
Number of Participants Who Experienced an Adverse Event (All Types/Grades) Within a Time Frame up to 24 Hours Following the Transfusion.23
PrimaryNumber of Participants Who Experienced an Adverse Event (AE) (All Types/Grades) Overall up to 7 Days (+/-1 Day) After the Transfusion.

The type and the grade of each adverse event will be categorized according to: * Association for the Advancement of Blood and Biotherapies (AABB) technical manual, 20th edition (2020) * Biomedical Excellence for Safer Transfusion (BEST) Collaborative review - Lancet 2016; 388: 2825-36 * Local AEs database (for reference) * ISO 14155-2020 definitions

Time frame:
7 days (+/-1 day)
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE) (All Types/Grades) Overall up to 7 Days (+/-1 Day) After the Transfusion.
ParticipantsHematologic MalignanciesAcute Burn
Number of Participants Who Experienced an Adverse Event (AE) (All Types/Grades) Overall up to 7 Days (+/-1 Day) After the Transfusion.47
SecondaryEvolution of the Hemoglobin Level Before and After the Transfusion.

The difference in measured hemoglobin (grams/dL) between pre-transfusion and up to 30 minutes post-transfusion.

Time frame:
pre-transfusion to up to 30 minutes post-transfusion
Reported as:
Mean · g/dL
Evolution of the Hemoglobin Level Before and After the Transfusion.
g/dLHematologic MalignanciesAcute Burn
Evolution of the Hemoglobin Level Before and After the Transfusion.1.20 ± 0.4940.25 ± 0.981
SecondaryCalculation of the Hemoglobin Increment After Transfusion Corrected for Patient Blood Volume and Hemoglobin Dose

The hemoglobin increment from each transfusion will be determined by calculating the difference between the subject's post-transfusion and pre-transfusion hemoglobin (g/dL). It will then be corrected for estimated subject blood volume and the amount of Hb transfused. The following equation used for the hemoglobin increment calculation: HgB Increment = (Subject's HgB level post-transfusion - Subject's HgB pre-transfusion)/ (total HgB transfused x Subject's BloodVolume) Equations for calculating the hemoglobin increment may be found in the following publication: Wendelbo Ø, Opheim EN, Hervig T, Felli Lunde TH, Bruserud Ø, Mollnes TE, Reikvam H. Cytokine profiling and post-transfusion haemoglobin increment in patients with haematological diseases. Vox Sang. 2018 Oct;113(7):657-668. doi: 10.1111/vox.12703. Epub 2018 Aug 29. PMID: 30159896.

Time frame:
28 days

No measurements were reported for this outcome.

SecondaryComparison of the Hemoglobin Level Before the Index Transfusion to That Prior to the Subsequent Transfusion

The difference in measured hemoglobin (grams/dL) between the pre-transfusion hemoglobin level for the study transfusion and the pre-transfusion hemoglobin level for the next scheduled transfusion.

Time frame:
28 days
Reported as:
Mean · g/dL
Comparison of the Hemoglobin Level Before the Index Transfusion to That Prior to the Subsequent Transfusion
g/dLHematologic MalignanciesAcute Burn
Comparison of the Hemoglobin Level Before the Index Transfusion to That Prior to the Subsequent Transfusion0.21 ± 1.1770.84 ± 2.065
SecondaryEvaluation of AEs From Enrollment, up to Prior to the Subsequent Transfusion or up to Day 28, Whichever Occurs First

Number of AEs that occur from enrollment, up to prior to the subsequent transfusion or up to Day 28, whichever occurs first

Time frame:
28 days
Reported as:
Number · adverse event
Evaluation of AEs From Enrollment, up to Prior to the Subsequent Transfusion or up to Day 28, Whichever Occurs First
adverse eventHematologic MalignanciesAcute Burn
Evaluation of AEs From Enrollment, up to Prior to the Subsequent Transfusion or up to Day 28, Whichever Occurs First47
SecondaryEvaluation of Subject's Blood Pressure Over the Course of the Transfusion and up to 15 Minutes Post-transfusion

Change in blood pressure (systolic; mmHg) from baseline up to 15 minutes post-transfusion.

Time frame:
baseline up to 15 minutes post-transfusion.
Reported as:
Mean · mmHg
Evaluation of Subject's Blood Pressure Over the Course of the Transfusion and up to 15 Minutes Post-transfusion
mmHgHematologic MalignanciesAcute Burn
Evaluation of Subject's Blood Pressure Over the Course of the Transfusion and up to 15 Minutes Post-transfusion-4.56 ± 6.521-3.40 ± 23.996
SecondaryEvaluation of Subject's Blood Pressure Over the Course of the Transfusion and up to 15 Minutes Post-transfusion

Change in blood pressure (diastolic; mmHg) from baseline up to 15 minutes post-transfusion.

Time frame:
baseline up to 15 minutes post-transfusion.
Reported as:
Mean · mmHg
Evaluation of Subject's Blood Pressure Over the Course of the Transfusion and up to 15 Minutes Post-transfusion
mmHgHematologic MalignanciesAcute Burn
Evaluation of Subject's Blood Pressure Over the Course of the Transfusion and up to 15 Minutes Post-transfusion-0.44 ± 7.3331.90 ± 9.219
SecondaryEvaluation of Subject's Respiratory Rate Over the Course of the Transfusion and up to 15 Minutes Post-transfusion

Change in respiratory rate (breaths per minute) from baseline to up to 15 minutes post-transfusion.

Time frame:
baseline to up to 15 minutes post-transfusion
Reported as:
Mean · breaths/min
Evaluation of Subject's Respiratory Rate Over the Course of the Transfusion and up to 15 Minutes Post-transfusion
breaths/minHematologic MalignanciesAcute Burn
Evaluation of Subject's Respiratory Rate Over the Course of the Transfusion and up to 15 Minutes Post-transfusion0.00 ± 2.062-1.10 ± 2.846
SecondaryEvaluation of Subject's SO2 Level Over the Course of the Transfusion and up to 15 Minutes Post-transfusion

Change in the amount of oxygen in the body (% S02 level), measured with a pulse oximeter, from baseline to up to 15 minutes post-transfusion.

Time frame:
baseline to up to 15 minutes post-transfusion
Reported as:
Mean · % O2 saturation
Evaluation of Subject's SO2 Level Over the Course of the Transfusion and up to 15 Minutes Post-transfusion
% O2 saturationHematologic MalignanciesAcute Burn
Evaluation of Subject's SO2 Level Over the Course of the Transfusion and up to 15 Minutes Post-transfusion0.22 ± 1.8560.00 ± 1.633
SecondaryEvaluation of Subject's Pulse Over the Course of the Transfusion and up to 15 Minutes Post-transfusion

Change in heart rate (beats per minute) from baseline to up to 15 minutes post-transfusion

Time frame:
baseline to up to 15 minutes post-transfusion
Reported as:
Mean · beats/min
Evaluation of Subject's Pulse Over the Course of the Transfusion and up to 15 Minutes Post-transfusion
beats/minHematologic MalignanciesAcute Burn
Evaluation of Subject's Pulse Over the Course of the Transfusion and up to 15 Minutes Post-transfusion-3.33 ± 6.1445.40 ± 16.263

Adverse events

Collected over Adverse Events reported up to 28 days post-transfusion, or up to subsequent transfusion episode, whichever comes first. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Hematologic Malignancies0/10 (0%)0/10 (0%)4/10 (40%)
Acute Burn0/12 (0%)1/12 (8.3%)6/12 (50%)
Most frequent serious events
Most frequent serious events
EventHematologic MalignanciesAcute Burn
OliguriaRenal and urinary disorders0/101/12
Wound infectionInfections and infestations0/101/12
Most frequent other events
Showing 10 of 18
Most frequent other events
EventHematologic MalignanciesAcute Burn
PyrexiaGeneral disorders1/103/12
NasopharyngitisInfections and infestations2/100/12
HeadacheNervous system disorders2/100/12
PruritusSkin and subcutaneous tissue disorders0/102/12
EpistaxisRespiratory, thoracic and mediastinal disorders1/100/12
Atrial fibrillationCardiac disorders1/100/12
Muscle spasmsMusculoskeletal and connective tissue disorders1/100/12
Catheter site extravasationGeneral disorders0/101/12
Pain of skinSkin and subcutaneous tissue disorders0/101/12
RashSkin and subcutaneous tissue disorders0/101/12

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Hematologic MalignanciesAcute BurnTotal
<=18 years000
Between 18 and 65 years21012
>=65 years8210
Age, Continuous
Age, Continuous(years)Hematologic MalignanciesAcute BurnTotal
Mean72.0 ± 16.4149.6 ± 19.4659.8 ± 21.08
Sex: Female, Male
Sex: Female, Male(Participants)Hematologic MalignanciesAcute BurnTotal
Female224
Male81018
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Hematologic MalignanciesAcute BurnTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White101121
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Hematologic MalignanciesAcute BurnTotal
Norway101222
08

Study locations

1 site
  • Haukeland University Hospital
    Bergen, 5021, Norway
09

References and documents

Publications

  • Yoshida T, Prudent M, D'alessandro A. Red blood cell storage lesion: causes and potential clinical consequences. Blood Transfus. 2019 Jan;17(1):27-52. doi: 10.2450/2019.0217-18. PubMed 30653459 ↗
  • Williams AT, Jani VP, Nemkov T, Lucas A, Yoshida T, Dunham A, D'Alessandro A, Cabrales P. Transfusion of Anaerobically or Conventionally Stored Blood After Hemorrhagic Shock. Shock. 2020 Mar;53(3):352-362. doi: 10.1097/SHK.0000000000001386. PubMed 31478989 ↗
  • D'Alessandro A, Yoshida T, Nestheide S, Nemkov T, Stocker S, Stefanoni D, Mohmoud F, Rugg N, Dunham A, Cancelas JA. Hypoxic storage of red blood cells improves metabolism and post-transfusion recovery. Transfusion. 2020 Apr;60(4):786-798. doi: 10.1111/trf.15730. Epub 2020 Feb 27. PubMed 32104927 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in May 2024, 20 months.

Results were first posted in May 2025, 1 year after primary completion.

Of 186 observational studies under Hematologic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 322. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2022
First posted
Sep 22, 2022
StartActual
Aug 24, 2022
Primary completionActual
May 16, 2024
CompletionActual
May 16, 2024
Results first posted
May 18, 2025
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05549232
Lead sponsor
Hemanext
Responsible party
Sponsor
First posted
Sep 22, 2022
Start date
Aug 24, 2022
Primary completion
May 16, 2024
Completion
May 16, 2024
Results posted
May 18, 2025
Last update
Jul 23, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion